Invention Grant
- Patent Title: CDCA1 epitope peptides for Th1 cells and vaccines containing the same
-
Application No.: US15411115Application Date: 2017-01-20
-
Publication No.: US10206989B2Publication Date: 2019-02-19
- Inventor: Yasuharu Nishimura , Yusuke Tomita , Ryuji Osawa
- Applicant: OncoTherapy Science, Inc.
- Applicant Address: JP Kanagawa
- Assignee: OncoTherapy Science, Inc.
- Current Assignee: OncoTherapy Science, Inc.
- Current Assignee Address: JP Kanagawa
- Agency: Kilpatrick Townsend & Stockton LLP
- Main IPC: A61K38/00
- IPC: A61K38/00 ; A61K39/00 ; C07K14/47 ; C12N5/0783 ; C07K16/28 ; C07K7/06 ; C07K7/08 ; C07K14/00 ; C07K16/30 ; C12N5/078

Abstract:
Isolated CDCA1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce CDCA1-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
Public/Granted literature
- US20180117135A9 CDCA1 EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME Public/Granted day:2018-05-03
Information query
IPC分类: